| Bioactivity | Hsp90-IN-16 (compound 16s) is an HSP90 inhibitor with high selectivity and potency against HER2-positive cancer cells. Hsp90-IN-16 exhibits high anti-proliferative capacity against HCC1954 breast cancer cells with an IC50 of 6 μM. Hsp90-IN-16 induces apoptosis by inhibiting HSP90 "client" proteins, including a key oncogenic receptor, HER2/neu[1]. |
| Invitro | Hsp90-IN-16 (0-25 μM; 72 h) shows an antiproliferative effect on three breast cancer cell lines (MCF7, MDA-MB-231 and HCC1954)[1].Hsp90-IN-16 (10, 15, 20 μM; 72 h) induces apoptosis in HCC1954 cells via inhibition of HSP90 “client” proteins including a key oncogenic receptor, HER2/neu[1]. Cell Proliferation Assay[1] Cell Line: |
| Name | Hsp90-IN-16 |
| Formula | C30H26FN3O6 |
| Molar Mass | 543.54 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Piven YA, et al. Novel O-acylated (E)-3-aryl-6,7-dihydrobenzisoxazol-4(5H)-one oximes targeting HSP90-HER2 axis in breast cancer cells. Bioorg Med Chem. 2022 Jan 1;53:116521. |